Abstract

A meta-analysis was conducted to figure out the long-term effectiveness of bortezomib in managing patients with multiple myeloma. To retrieve relevant literature, the Chinese National Knowledge Infrastructure and Wanfang databases were searched using the keywords bortezomib, multiple myeloma, and long-term efficacy. Additionally, Embase, the Web of Science, PubMed, and Cochrane Library databases were queried using the terms bortezomib, multiple myeloma, and long-term effect. Two assessors utilized Cochrane scoring to evaluate the quality of the articles. Retrieve pertinent data from the included research articles and analyze it using RevMan 5.4 software to evaluate the effectiveness of bortezomib through meta-analysis. Ten publications were incorporated into the meta-analysis. According to the findings of the meta-analysis, patients undergoing consolidation therapy for multiple myeloma exhibited significantly superior progression-free survival and overall survival outcomes when treated with bortezomib compared to those who were not. In terms of overall survival during consolidation therapy, there was no notable distinction observed between the two groups of patients. Additionally, the funnel plot analysis indicated the absence of any significant publication bias. This meta-analysis unequivocally establishes the notable advantages of utilizing bortezomib as an initial medication choice for consolidation and maintenance therapy in multiple myeloma. Significant enhancements in both progression-free survival and overall survival were observed, underscoring its efficacy.